자궁근종 치료제 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of uterine fibroid drugs Market

The global uterine fibroid drugs market is projected to witness significant growth during the forecast period, driven by rising prevalence of uterine fibroids and increasing demand for non-invasive therapeutic options. The market was valued at USD 2.97 billion in 2025, projected to reach USD 3.38 billion in 2026, and is expected to grow to USD 9.71 billion by 2034, exhibiting a CAGR of 16.28%. North America dominated the market in 2025 with a 45.56% share, attributed to robust healthcare infrastructure, high diagnosis rates, and increasing adoption of innovative therapies.

Uterine fibroids, also known as leiomyomas or myomas, are benign, non-cancerous growths of the uterine smooth muscle and connective tissue. While some cases remain asymptomatic, symptomatic fibroids can cause heavy menstrual bleeding, pelvic pain, anemia, urinary complications, and fertility issues. Factors such as sedentary lifestyle, obesity, delayed menopause, and metabolic disorders are contributing to the rising prevalence of uterine fibroids, boosting the global demand for effective pharmacological interventions.

Key players in the market, including AbbVie Inc., Neurocrine Biosciences, and Sumitomo Pharma, are actively developing pipeline candidates to meet the growing need for effective uterine fibroid treatments.

Market Dynamics

Market Drivers

The rising burden of uterine fibroids is the primary growth driver, affecting up to 70-80% of women by age 50, with a significant proportion experiencing severe symptoms. Women increasingly prefer uterus-preserving and fertility-friendly drug therapies over surgical options. The rising symptomatic patient population widens the addressable market, leading to increased adoption of novel therapies such as GnRH agonists, antagonists, and selective progesterone receptor modulators.

For example, according to the NIH (2020), symptomatic uterine fibroids can cause abnormal uterine bleeding, anemia, pelvic pain, urinary issues, and infertility, highlighting the growing demand for medical interventions.

Market Restraints

Severe adverse effects such as bone density loss, hot flashes, and cardiovascular risks can reduce patient adherence and limit treatment duration. These safety concerns restrict long-term usage and influence physicians' prescribing patterns, particularly for women of reproductive age. For instance, in the ELARIS UF-1 and UF-2 trials (2021), approximately 10% of women discontinued treatment due to adverse reactions.

Market Opportunities

Increasing research initiatives are creating lucrative growth opportunities. Academic collaborations, government funding, and biotech-pharma partnerships are driving the development of next-generation therapies, including injectable alternatives and novel oral GnRH antagonists.

For instance, in May 2022, researchers at Duke University collaborated to develop a minimally invasive, effective injectable therapy for uterine fibroids, expanding treatment options.

Market Challenges

Regulatory stringency and safety risks pose challenges to market growth. Women's health therapies require long-term safety data, especially regarding fertility, hormonal balance, and adverse effects. Regulatory scrutiny increases development costs and timelines, limiting smaller biopharma firms' ability to compete. For example, Kissei Pharmaceutical (2022) faced rigorous review processes for its GnRH antagonist, Linzagolix.

Global Market Trends

A prominent trend is strategic collaborations among key market players, which accelerates R&D, expands market reach, and mitigates development risks. Notable collaborations include Myovant Sciences and Pfizer (2020) for commercialization of relugolix in North America, enabling faster market access and expanded patient reach.

Segmentation Analysis

By Drug Class:

• GnRH agonists dominated with a 54.18% share in 2026, widely adopted for rapid fibroid shrinkage and bleeding control.
• GnRH antagonists are expected to grow significantly due to expanding pipelines and regulatory approvals.

By Type:

• Intramural fibroids segment captured the largest share with 53.40% in 2026, due to high prevalence and symptom severity.
• Submucosal fibroids are projected to grow at 14.14% CAGR.

By Route of Administration:

• Parenteral (injectables) segment held 72.72% share in 2026, favored for sustained-release formulations and proven efficacy.
• Oral drugs are growing at 29.5% CAGR, offering ease of administration and better adherence.

By Application:

• Shrinkage segment dominated with a 56.42% share in 2026, providing both symptomatic relief and disease modification.
• Pain management segment is projected to grow at 14.92% CAGR.

By Distribution Channel:

• Retail pharmacies & drug stores held a 43.1% share in 2025, due to wide accessibility.
• Hospital pharmacies are projected to grow at 13.33% CAGR.
• Online pharmacies are expanding, driven by e-commerce platforms.

Regional Outlook

North America: Market valued at USD 1.35 billion in 2025, projected to USD 1.54 billion in 2026, with the U.S. alone reaching USD 1.46 billion. Growth is supported by high prevalence, advanced healthcare infrastructure, and strategic collaborations.

Europe: Market estimated at USD 0.87 billion in 2026, second-highest growth due to awareness programs, advanced therapies, and reimbursement policies. Major contributors include the U.K., Germany, and France.

Asia Pacific: Market projected to reach USD 0.7 billion in 2026, with India at USD 0.09 billion and China at USD 0.25 billion.

Latin America: Estimated at USD 0.15 billion in 2026, driven by improving healthcare access and awareness.

Middle East & Africa: GCC countries estimated at USD 0.05 billion in 2025.

Competitive Landscape

The market is semi-consolidated, dominated by AbbVie, Neurocrine Biosciences, Sumitomo Pharma, and Pfizer. Strategic activities include R&D investments, collaborations, and patent filings to expand their global presence. For instance, in June 2025, Altin Biosciences received a Notice of Allowance for its lead drug candidate ABC-105/ABC-205 for non-hormonal treatment of uterine fibroids. Other players include Kissei Pharmaceutical, ObsEva SA, and TiumBio.

Key Industry Developments

• October 2025: Knight Therapeutics relaunched MYFEMBREE in Canada for heavy menstrual bleeding associated with uterine fibroids.
• October 2025: Searchlight Pharma secured Canadian rights for Linzagolix.
• February 2025: Kissei Pharmaceutical submitted NDA for Linzagolix in Japan.
• December 2024: Theramex received European Commission approval for extended Yselty indication.

Conclusion

The global uterine fibroid drugs market is set to grow from USD 2.97 billion in 2025 to USD 9.71 billion by 2034, at a CAGR of 16.28%, driven by increasing prevalence, technological innovation, and expanding treatment options. North America leads due to robust healthcare infrastructure, while emerging markets offer growth potential. Strategic collaborations, R&D investments, and increasing adoption of oral and injectable therapies are expected to further enhance market growth, offering patients effective, non-surgical management of uterine fibroids worldwide.

Segmentation By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Region

By Drug Class * GnRH Antagonists

• GnRH Agonists
• Others

By Type * Intramural Fibroid

• Submucosal Fibroid
• Others

By Route of Administration * Oral

• Parenteral

By Application * Shrinkage

• Pain Management
• Others

By Distribution Channel * Hospital Pharmacies

• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Geography * North America (By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug Class, Type, Route of Administration, Application, Distribution Channel, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Regulatory Scenarios, By Key Countries/Regions
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Epidemology of Uterine Fibroids, By Key Countries/ Regions, 2025
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. GnRH Antagonists
  • 5.1.2. GnRH Agonists
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. Intramural Fibroid
  • 5.2.2. Submucosal Fibroid
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
• 5.4. Market Analysis, Insights and Forecast - By Application
  • 5.4.1. Shrinkage
  • 5.4.2. Pain Management
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital Pharmacies
  • 5.5.2. Retail Pharmacies & Drug Stores
  • 5.5.3. Online Pharmacies
• 5.6. Market Analysis, Insights and Forecast - Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. GnRH Antagonists
  • 6.1.2. GnRH Agonists
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. Intramural Fibroid
  • 6.2.2. Submucosal Fibroid
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
• 6.4. Market Analysis, Insights and Forecast - By Application
  • 6.4.1. Shrinkage
  • 6.4.2. Pain Management
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital Pharmacies
  • 6.5.2. Retail Pharmacies & Drug Stores
  • 6.5.3. Online Pharmacies
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. GnRH Antagonists
  • 7.1.2. GnRH Agonists
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. Intramural Fibroid
  • 7.2.2. Submucosal Fibroid
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
• 7.4. Market Analysis, Insights and Forecast - By Application
  • 7.4.1. Shrinkage
  • 7.4.2. Pain Management
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital Pharmacies
  • 7.5.2. Retail Pharmacies & Drug Stores
  • 7.5.3. Online Pharmacies
• 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Italy
  • 7.6.5. Spain
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. GnRH Antagonists
  • 8.1.2. GnRH Agonists
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. Intramural Fibroid
  • 8.2.2. Submucosal Fibroid
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
• 8.4. Market Analysis, Insights and Forecast - By Application
  • 8.4.1. Shrinkage
  • 8.4.2. Pain Management
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital Pharmacies
  • 8.5.2. Retail Pharmacies & Drug Stores
  • 8.5.3. Online Pharmacies
• 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. Southeast Asia
  • 8.6.5. Australia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. GnRH Antagonists
  • 9.1.2. GnRH Agonists
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. Intramural Fibroid
  • 9.2.2. Submucosal Fibroid
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
• 9.4. Market Analysis, Insights and Forecast - By Application
  • 9.4.1. Shrinkage
  • 9.4.2. Pain Management
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital Pharmacies
  • 9.5.2. Retail Pharmacies & Drug Stores
  • 9.5.3. Online Pharmacies
• 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. GnRH Antagonists
  • 10.1.2. GnRH Agonists
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Type
  • 10.2.1. Intramural Fibroid
  • 10.2.2. Submucosal Fibroid
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
• 10.4. Market Analysis, Insights and Forecast - By Application
  • 10.4.1. Shrinkage
  • 10.4.2. Pain Management
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital Pharmacies
  • 10.5.2. Retail Pharmacies & Drug Stores
  • 10.5.3. Online Pharmacies
• 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.2.1. AbbVie Inc.
  • 11.2.2. Sumitomo Pharma Co., Ltd.
  • 11.2.3. Pfizer Inc.
  • 11.2.4. Kissei Pharmaceutical Co., Ltd.
  • 11.2.5. ObsEva SA
  • 11.2.6. Neurocrine Biosciences, Inc.
  • 11.2.7. TiumBio Co., Ltd.
  • 11.2.8. Daewon Pharmaceutical Co., Ltd.